# AALL1521 (NCT02723994)

> A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02723994
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: Leukemia
- Interventions: Ruxolitinib; Asparaginase Erwinia Chrysanthemi; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Leucovorin Calcium; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Thioguanine; Vincristine Sulfate
- Enrollment: 171
- Primary outcome: Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms
- Primary outcome: Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1

## Indexed commentary on AALL1521 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aall1521-nct02723994